NCT06403709 2024-09-24Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC PatientsCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Active not recruiting35 enrolled